| Systemic Lupus Erythematosus |
1 |
1 |
| Biologic Therapy |
0 |
0.95 |
| CAR-T |
0 |
0.99 |
| T-Lymphocyte |
0 |
0.9 |
| Lupus |
0 |
0.8 |
| Lupus Nephritis |
0 |
0.28 |
| Refractory |
0 |
0.85 |
| Antigens |
0 |
0.18 |
| Remission |
0 |
0.88 |
| Monoclonal Antibody |
0 |
0.15 |
| Multiple Myeloma |
0 |
0.15 |
| Antineoplastic Drug |
0 |
0.14 |
| Immunotherapy |
0 |
0.12 |
| Non-Hodgkin Lymphoma (NHL) |
0 |
0.12 |
| Tennessee |
0 |
0.12 |
| Receptors |
0 |
0.09 |
| Rheumatoid Arthritis |
0 |
0.09 |
| B-Cell Lymphoma |
0 |
0.07 |
| Toxicology |
0 |
0.07 |
| Acute Leukemia |
0 |
0.06 |
| Arthritis |
0 |
0.06 |
| Lymphoma |
0 |
0.06 |
| Nephritis |
0 |
0.06 |
| Pericarditis |
0 |
0.06 |
| Tissue |
0 |
0.06 |
| Acute Lymphoblastic Leukemia |
0 |
0.04 |
| Heart Failure (HF) |
0 |
0.04 |
| Libman-Sacks Endocarditis |
0 |
0.04 |
| Lysosomal Storage Disease |
0 |
0.04 |
| Multiple Sclerosis |
0 |
0.04 |
| Autoimmune Disease |
0 |
0.03 |
| Cancer |
0 |
0.03 |
| Clinical Research |
0 |
0.03 |
| Cytokines |
0 |
0.03 |
| Endocarditis |
0 |
0.03 |
| Europe |
0 |
0.03 |
| Glucocorticoid |
0 |
0.03 |
| Grant |
0 |
0.03 |
| I-Cell Disease |
0 |
0.03 |
| Leukemia |
0 |
0.03 |
| Pathogenesis |
0 |
0.03 |
| Plasma |
0 |
0.03 |
| Proteinuria |
0 |
0.03 |
| Residency |
0 |
0.03 |